Who is sponsoring NCT07137481?

NCT07137481 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT07137481?

Interventions in NCT07137481: C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine, Cyclophosphamide.

What condition does NCT07137481 study?

NCT07137481 studies Hematological Malignancies.

Is NCT07137481 still recruiting?

NCT07137481 is currently not yet recruiting. Last updated 4 March 2026.

Last reviewed 2026-03-04 · How we verify

NCT07137481

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies

Not yet recruiting Phase 2 Last updated 4 March 2026

What this trial tests

Phase 2 trial testing C9/CD5CAR/IL-15 NK cells in Hematological Malignancies in 70 participants. Not yet recruiting.

Timeline

28 February 2027

Primary endpoint
31 July 2030

31 July 2032

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	70
Start date	28 February 2027
Primary completion	31 July 2030
Estimated completion	31 July 2032
Sites	1 location across United States

Drugs / interventions tested

C9/CD5CAR/IL-15 NK cells — full drug profile →
Rituximab — full drug profile →
Fludarabine (FLUDARABINE) — full drug profile →
Cyclophosphamide (cyclophosphamide) — full drug profile →

Conditions studied

Hematological Malignancies — all drugs for Hematological Malignancies →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

Adults 18 to 80, any sex, with Hematological Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To determine the safety and efficacy (1-year PFS) of iC9/CD5CAR/IL-15 NK cells as consolidation in patients with aggressive T-cell malignances in first remission.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hematological Malignancies

Currently open trials in the same condition.

NCT07220616 — A First-in-Human Trial of DS3790a in Participants With Hematological Malignancies · Phase 1, PHASE2 · recruiting
NCT06584955 — Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients With Hematological Malignancies · NA · active not recruiting
NCT06387082 — A Clinical Study of HMPL-506 in Patients With Hematological Malignancies · Phase 1 · recruiting
NCT06150469 — Efficacy of Inhaled Aromatherapy on Nausea and Vomiting in Hematological Malignancies · NA · recruiting
NCT06179511 — Study of AZD9829 in CD123+ Hematological Malignancies · Phase 1, PHASE2 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
NCT07527169 — A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07137481 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 4 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07137481.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing